Clinical trials: Autoimmune Thrombocytopenia
Immune Thrombocytopenia
Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of cyclosporin plus standard steroid compared to standard steroid monotherapy for the first-line treatment of adults with primary immune…
- Trial name
- NCT05459649
- Testing
- Cyclosporine Oral Product, Prednisone
- Where
- China
- Volunteers
- 253 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia (ITP)
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
The objective of evaluating the pharmacokinetics and pharmacodynamics of romiplostim in patients with immune thrombocytopenia.
- Trial name
- NCT02868060
- Testing
- Romiplostim
- Where
- 5 sites in China
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd.
Primary Immune Thrombocytopenia (ITP)
Study of Immune Thrombocytopenia Pathogenesis:
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells.
- Trial name
- PTI PARI (NCT02042560)
- Testing
- Blood samples, Spleen samples
- Where
- 3 sites in France
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Idiopathic Thrombocytopenia Purpura
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone
In this prospective and retrospective chart review, investigators will evaluate the response rates and duration of response for patients with relapsed and refractory idiopathic thrombocytopenic purpura (ITP) who have been treated…
- Trial name
- Dex/Rituxan (NCT02050581)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Weill Medical College of Cornell University
Primary Immune Thrombocytopenia
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with…
- Trial name
- VAYHIT2 (NCT05653219)
- Testing
- Ianalumab, Eltrombopag
- Where
- 74 sites in United States, Argentina and 22 more
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Sjogren Syndrome With Other Organ Involvement
Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS
This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus combined with Glucocorticoid for Sjogren's syndrome patients with severe thrombocytopenia.
- Trial name
- NCT05694130
- Testing
- Prednisolone, Tacrolimus
- Volunteers
- 110 people
- Sponsor
- Peking Union Medical College Hospital
Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
This study will compare treatment with 3 courses of high-dose dexamethasone versus treatment with prednisone, for patients recently diagnosed with immune thrombocytopenic purpura (ITP).
- Trial name
- ITP^2 (NCT00991939)
- Testing
- Dexamethasone USP Micronized, Prednisone
- Where
- 18 sites in United States
- Volunteers
- 8 people
- Sponsor
- Carelon Research
Immune Thrombocytopenic Purpura
" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "
Immune thrombocytopenia is an acquired autoimmune disease, in which platelets are opsonized by auto-antibodies and destroyed by phagocytic cells .Genetic polymorphisms in the immune mediators have been suggested to play a pivotal…
- Trial name
- NCT05585944
- Testing
- Genotyping of rs1883832C/T related single-nucleotide polymorphism
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenia
The Study of Different Dose Rituximab in the Treatment of ITP
The project was undertaking by Qilu Hospital of Shandong University in China. In order to compare the efficacy, safety and response duration of different dose of rituximab in patients primary immune thrombocytopenia(pITP).
- Trial name
- NCT03258866
- Testing
- Rituximab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shandong University
Hereditary Spherocytosis, Idiopathic Thrombocytopenic Purpura
Single Incision Versus Standard Laparoscopic Splenectomy
This is a prospective trial of single incision versus standard 4-port laparoscopic splenectomy. The hypothesis is that there may be a difference in wound infection rates, operative time, doses of analgesics post-operatively, and…
- Trial name
- NCT01276561
- Testing
- Single Incision Splenectomy, Laparoscopic Splenectomy
- Where
- United States
- Sponsor
- Children's Mercy Hospital Kansas City
Immune Thrombocytopenic Purpura
Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
Octagam is a solvent/detergent-treated human normal immunoglobulin (IGIV) solution for intravenous administration. Octagam 5% is currently registered in about 80 countries.
- Trial name
- NCT00426270
- Testing
- Octagam 10%
- Where
- Austria
- Volunteers
- 116 people
- Sponsor
- Octapharma
Primary Immune Thrombocytopenia (ITP)
rhTPO Dose Escalation vs Eltrombopag Switch in ITP
This study is a prospective, multicenter, randomized controlled study, planning to enroll 110 ITP patients who failed to respond to conventional-dose rhTPO (300 IU/kg/d) after 14 days of treatment (PLT < 30×10⁹/L).
- Trial name
- NCT07476846
- Testing
- Recombinant Human Thrombopoietin（rhTPO）, Eltrombopag PfOS
- Volunteers
- 112 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Idiopathic Thrombocytopenic Purpura
Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?
Idiopathic thrombocytopenic purpura (ITP) is a benign hematological disorder characterized by isolated thrombocytopenia. Development of antiplatelet autoantibodies is the main pathogenetic mechanism in patients with ITP.
- Trial name
- NCT04128358
- Testing
- Serological assay for blood born viral hepatitis, Quantitative microbiological test for HCV
- Where
- Egypt
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assiut University
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had…
- Trial name
- NCT07297563
- Testing
- Rituximab, Daratumumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Idiopathic Thrombocytopenic Purpura
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
The purpose of this study is to describe the number of months with a platelet response over a 12 month treatment period and to describe ITP remission rates in adults with ITP receiving romiplostim.
- Trial name
- NCT01143038
- Testing
- Romiplostim
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 75 people
- Sponsor
- Amgen
Idiopathic Thrombocytopenic Purpura
Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP
It is a phase III multicenter randomized double-blinded comparative study of clinical efficacy and safety of GNR-069 and Nplate in patients with idiopathic thrombocytopenic purpura
- Trial name
- NCT05220878
- Testing
- GNR-069, Nplate
- Where
- 18 sites in Russia
- Volunteers
- 160 people
- Sponsor
- AO GENERIUM
ITP
Anti-BCMA CAR T-Cell Therapy for R/R ITP
This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy（BCMA CAR-T）for patients with relapse/refractory Immune…
- Trial name
- NCT05315778
- Testing
- autologous anti-BCMA chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Immune Thrombocytopenia
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP
The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsule plus high-dose dexamethasone for the treatment of…
- Trial name
- NCT05023915
- Testing
- dexamethasone, diammonium glycyrrhizinate enteric-coated capsule
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Shandong University
Immune Thrombocytopenia
Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
The main purpose of this extended study is to enable subjects who are currently receiving the PartB experimental drug in the HR-TPO-ITP-III-PED clinical trial .To continue receiving the experimental drug after the completion of…
- Trial name
- NCT05685420
- Testing
- Herombopag
- Volunteers
- 117 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
Some patients with antibody-mediated autoimmune hematological diseases (warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (cAIHA) and immune thrombocytopenia (ITP)) shows no or only minor and transient response to…
- Trial name
- Ixa-Cyto (NCT03965624)
- Testing
- Ninlaro
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris